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Background: Porcine endogenous retroviruses (PERVs) released from pig tissue can infect selected 
human cells in vitro and therefore represent a safety risk for xenotransplantation using pig cells, 
tissues, or organs. Although PERVs infect cells of numerous species in vitro, attempts to establish 
reliable animal models failed until now. Absence of PERV transmission has been shown in first 
experimental and clinical xenotransplantations; however, these trials suffered from the absence of 
long-term exposure (transplant survival) and profound immunosuppression. 
 
Methods: We conducted infectivity studies in rhesus monkeys, pig-tailed monkeys, and baboons under 
chronic immunosuppression with cyclosporine A, methylprednisolone, and the rapamycin derivative. 
These species were selected because they are close to the human species and PERVs can be 
transmitted in vitro to cells of these species. In addition, the animals received twice, a C1 esterase 
inhibitor to block complement activation before inoculation of PERV. In order to overcome the 
complications of microchimerism, animals were inoculated with high titers of cell-free PERV. In 
addition, to enable transmission via cell–cell contact, some animals also received virus-producing 
cells. For inoculation the primate cell-adapted strain PERV/5_ was used which is characterized by a 
high infectious titer. Produced on human cells, this virus does not express alpha 1,3 Gal epitopes, 
does not contain porcine antigens on the viral surface and is therefore less immunogenic in non-
human primates compared with pig cell-derived virus. Finally, we present evidence that PERV/5_ 
productively infects cells from baboons and rhesus monkeys. 
 
Results: In a follow-up period of 11 months, no antibody production against PERV and no integration 
of proviral DNA in blood cells was observed. Furthermore, no PERV sequences were detected in the 
DNA of different organs taken after necropsy. 
 
Conclusion: These results indicate that in a primate model, in the presence of chronic 
immunosuppression, neither the inoculation of cellfree nor cell-associated PERV using a virus already 
adapted to primate cells results in an infection; this is despite the fact that peripheral blood 















The widening gap between patients waiting for transplantation because of the ever increasing 
shortage of human donor organs have to be bridged by modern, innovative approaches in 
transplantation medicine. Xenotransplantation, the transplantation of living cells, tissues, or organs 
across species, is among the most promising approaches. However, xenotransplantation is associated 
with immunological rejection and/or physiological incompatibility of the xenotransplant as well as with 
the potential xenogenic transmission of micro-organisms [1–4]. It is anticipated that these problems 
can be solved by the use of genetically modified pigs [5,6] and the generation 
of more effective immunsuppressive regimens.  
 
While most pathogens can be eliminated by specified pathogen-free breeding, this derivation 
technology is not expected to affect the potential transmission of porcine endogenous retroviruses 
(PERV) as they are an integral part of all pig genomes. Generally, trans-species transmissions occur 
in nature and result either in immunodeficiencies (e.g., human immunodeficiency viruses: HIV-1 and 
HIV-2) and/or tumors (e.g., feline leukemia virus, FeLV; Koala retrovirus, KoRV) [7]. Although PERVs 
are able to infect several human cell types in vitro [8–12], the potential to infect humans in vivo and 
possibility to cause diseases remains to be established. Exploratory clinical xenotransplantation trials 
including ex vivo perfusion allowing short-term contact of human recipients to living porcine cells or 
tissues have not resulted in transmission of PERV [13–21]. Similarly, investigations of non-human 
primates that had received porcine cells or organs showed no 
evidence of PERV infection [22–27]. Although PERV transmission was not investigated in more 
recent preclinical experiments with the longest ever survival time of xenotransplants, no signs of a 
retroviral disease were reported [28–30].  
 
In an effort to establish an animal model most closely to man, three non-human primate species, 
rhesus monkeys, pig-tailed monkeys, and baboons under clinically relevant immunosuppression were 
inoculated with high titers of PERV. Two routes of virus administration were studied, namely, 
inoculation of cell-free virus and of cell-associated virus. During 11 month follow-up we assessed 
antibody production and the presence of PERV mRNA in the plasma. Furthermore, no PERV proviral 
sequences were detected in the DNA of blood cells or in the DNA of different organs taken after 
necropsy. Despite chronic, clinically relevant immunosuppression we were unable to document in vivo 
infection after inoculation of cell-free PERV or cell-associated PERV, while primary cells of the same 








Either cell-free virus containing supernatant of PERV/5_-producing 293 cells or virus-producing 
cells were used. PERV/5_ was derived from PERVNIH/ 3_ which is a recombinant PERV-A/C with 
PERV-A tropism (kindly provided by C. Wilson, FDA,WashingtonDC,USA[31])byserialpassaging on 
uninfected 293 cells. PERV/5_ is characterized by very high virus titers and genetic alterations in the 






Virus-containing supernatant produced by 1 · 107 PERV/5_-infected 293 cells was taken 3 days after 
the last medium change, and subsequently serially diluted in eight replicas, transferred to a 96-well 
plate with 3 · 104/well uninfected 293 cells, and incubated for 24 h at 37 _C. On the following day, the 
supernatant was removed and the cells were washed and cultured for 4 weeks, splitting the cells every 
3 to 4 days. To assess infection, a fraction of the cells was transferred to a poly-d-lysine-coated 96-
well plate on a weekly basis and washed twice with phosphate-buffered saline followed by fixation with 
methanol overnight at )20 _C and assessment of recombinant p15E of PERV using an 
immunoperoxidase method described previously [33]. 
 
  
In vitro infection 
 
Ten millilitre of virus-containing supernatant produced during a 3 day culture of 1 · 107 PERV/5_- 
producing 293 cells (titer 1 · 107 TCID50/ml) (tissue culture infectious doses), PERV-A and –B 
producing 293 cells (titer 1 · 103.2 TCID50/ml), and PK-15 cells (titer 102.3 TCID50/ml) were added 
cell-free to 5 · 106 peripheral blood mononuclear cells (PBMCs) of rhesus monkeys, pig-tailed 
monkeys, and baboons cultured in 10 ml RPMI 1640 (Invitrogen, Karlsruhe, Germany), respectively, 
and incubated for 24 h at 37 _C. After the incubation, the supernatant was removed; cells were 
washed twice, and recultured in 20 ml fresh medium for 10 days. Integration of PERV proviral DNA 
into the genome of infected cells was demonstrated by PCR using primers specific for PERV pol, gag, 
and env. Productive infection was shown by reverse transcriptase (RT) activity in the supernatant as 





Rhesus monkeys (Macaca mulatta; #178: male, 10 yr old, 10.4 kg weight; #179: male, 11 yr old, 9.5 
kg weight; #180: male, 12 yr old, 11 kg weight), pig-tailed monkeys (Macaca nemestrina; # 6506: 
male, adult, 13.7 kg weight; # 6501 male, 8 yr old, 11 kg weight), and baboons (Papio hamadryas; 
#6614: female, 8 yr old, 11.8 kg weight; #7341: female, 7 yr old, 11.6 kg weight) were used. Animals 
were housed at the Paul-Ehrlich Institute, Langen, Germany, and experiments were performed 





All animals received daily an intramuscular injection of 10 mg/kg cyclosporine A (Cs-A, Sandimmune; 
Novartis Pharma AG, Basel, Switzerland) and 0.8 mg/kg of methylprednisolone acetate (Depo-Merol; 
Upjohn, Kalamazoo, MI, USA), and a subcutaneous injection of 0.075 mg/kg RAD (Novartis Pharma 
AG). The dose levels of these drugs were selected based on exploratory tolerability/ pharmacokinetic 
studies associated with efficacy in transplantation studies [34–36]. Injection of Cs-A was started 5 or 
10 days before PERV inoculation (Fig. 1). Fifteen mg/kg methylprednisolone sodium succinate (Solu-
Medrol; Upjohn) was given intravenously on the day of virus inoculation. Five hundred units of the 
Complement component (C1)-esterase inhibitor Berinert_ HS (Aventis Behring, Marburg, Germany) 
were injected intravenously 3 days before and on the day of the second virus inoculation. This inhibitor 
was used because gamma retroviruses can be lysed directly by interaction of complement with the 
transmembrane envelope protein p15E [37]. 
 
 
PERV inoculation schedule 
 
The animals were inoculated three times (days 0, 270, and 284) (Fig. 1, Table 1). Cell-free PERV/5_ 
(titer 1 · 107 TCID50/ml) and PERV/5_-producing 293 cells (titer of their supernatant 1 · 107 
TCID50/ml) were inoculated. Rhesus monkey #179 died on day 14 due to bacterial septicemia 
presumably related to overimmunosuppression. 
 
 
Blood sample collection 
 
Before virus inoculation and every week thereafter, heparinized blood was taken for immunological 
testing and DNA isolation. In parallel, EDTA blood was taken for measuring the level of Cs-A, 





Concentrations of methylpredisolone were measured by high-performance liquid chromatography at 
the Institute of Toxicological Chemistry, Humboldt University, Berlin, Germany (limit of detection: 10 
ng/ml). Concentrations of Cs-A were measured using a EMIT 2000_ detection assay (Syva Company, 
Cupertino, CA, USA) at the Department of Nephrological Surgery, University Hospital, Frankfurt, 
Germany (limit of detection: 20 ng/ml). Concentrations of RAD were measured using liquid 
chromatography/mass spectrometry at Drug Metabolism and Pharmacokinetics (Novartis Pharma AG; 
  
limit of detection: 2 ng/ml). Concentrations of Berinert_ HS C1-esterase inhibitor were measured using 






DNA from PBMCs was isolated using preparation kits from Qiagen GmbH (Hilden, Germany). After 
necropsy, spleen, kidneys, heart, lung, liver, and lymph nodes were taken and stored at )80 _C. 
Organs were divided and analyzed independently at the Robert Koch Institute (Berlin, Germany) and 
Immerge BioTherapeutics (Boston, MA, USA). DNA was isolated using either standard phenol/ 
chloroform techniques (Robert Koch Institute) or QIAamp kits (Qiagen; Immerge BioTherapeutics) 





This method was performed at the Robert Koch Institute. For the detection of provirus, primers specific 
for the pol [38] the gag [13], and the env gene of PERV-A [39] were used (Table 2). To control the 
quality of DNA, primers specific for the human b-actin gene (Clonetech, Mountain View, CA, USA) or 
for the baboon endogenous virus (BaEV) [40] were used. To identify human 293 cells, primers specific 
for adenovirus 5 (Ad5) sequences [41] were used. For amplification the standard PCR program ([95 
_C, 10 min] · 1, [95 _C, 1 min, 55 _C, 1 min, 72 _C, 1 min] · 35, [72 _C, 7 min] · 1) was applied. To 
analyze the sensitivity of the PCR, 1 · 106 uninfected 293 cells were seeded in each well of a 96-well 
plate and were mixed with PERV/5_-producing 293 cells which were serially diluted in eight replicates 
from 2 · 104 to 1 cell. After cells were lyzed for 3 h at 56 _C in a lysis reagent containing 20 mg/ml 
proteinase K (Life Technologies, Eggenstein-Leopoldshafen, Germany) and PCR buffer (50 mm KCl; 
1.5 mm MgCl2; 10 mm Tris–HCl; pH 8.4; Applied Biosystems, Foster City, CA, USA), enzyme was 
subsequently inactivated by incubation at 95 _C for 10 min. Five ll of this crude extract were used as 
template in a nested PCR using primers specific for PERV pol. One single PERV-producing cell was 
detected on the background of 1 · 106 uninfected 293 cells. 
 
 
Real time PCR 
 
This method was performed at Immerge BioTherapeutics using primers and probes for the swine 
leukocyte antigen (SLA) and PERV pol (Table 2). Real-time quantitative PCR was performed on 100 
ng of DNA in a 25 ll reaction mix (QuantiTect Probe PCR Kit, Qiagen) containing 12.5 lmoles of sense 
and antisense primers. The reactions were cycled at 50 _C for 2 min, 95 _C 10 min, followed by 40 
cycles of 95 _C 15 s, 60 _C 60 s. All reactions were quantified against known copy number plasmid 











Viral RNA from plasma of the inoculated animals was isolated using the high pure viral RNA isolation 
kit (Roche Diagnostic GmbH, Mannheim, Germany). RNA was reverse transcribed using an one-step 
RT-PCR kit (Life Technologies GmbH) and cDNA was screened for PERV using PCR carried out with 









Western blot assays 
 
Western blots were performed as described [17] using PERV concentrated by ultracentrifugation, 
purified by sucrose gradient centrifugation, and subjected to denaturing 10% sodium dodecyl sulfate– 
polyacrylamide gel electrophoresis in tricine buffer. Proteins were transferred to polyvinylidene 
difluoride membranes by electroblotting. Membranes were blocked using 0.1% Tween 20 and 1% 
bovine serum albumin in Tris-buffered saline. Sera were incubated for 12 h at 4 _C and 
peroxidasecoupled species-specific anti-IgG antiserum for 2 h at room temperature. Antibody binding 
was visualized using metal-enhanced diaminobenzidine (Pierce, Rockford, IL, USA) and hydrogen 
peroxide. As positive control, a goat serum against recombinant p15E, goat serum against p27 of 
FeLV 
cross-reacting with p27 of PERV, and a rabbit antiserum against purified PERV were used [17,20]. 
 
 
Measurement of RT 
 
Reverse transcriptase activity was measured in supernatants of overnight cultures of PERV/5_- 
producing 293 cells, PERV-A and -B producing 293 cells, and PERV-producing PK-15 cells as well 




Enzyme-linked immuno assay 
 
Enzyme-linked immunoassays were performed as described[17]using96-wellplatescoatedwith0.2 lg/ 
well of recombinant p15E or of recombinant Gag of PERV,respectively. Plates were blocked with 100 
ll/ well 3% bovine serum albumin (Serva, Heidelberg, Germany) in phosphate-buffered saline. Sera 
were diluted 1 : 100 in blocking solution and 100 ll/well were incubated for 1 h at 37 _C. Horseradish 
peroxidaselabelledproteinGorhumanantiIgGsecondary antibodies (Sigma, St. Louis, MO, USA), 
respectively, were diluted 1 : 2000 and 100 ll/well were incubated for 1 h at room temperature. 







Validation of model and methods 
 
The outcome of an in vivo infection study in adult immunosuppressed animals is mainly determined by 
three different parameters: (i) the titer of the inoculated virus; (ii) the susceptibility of the inoculated 
animal to infection; and (iii) the exposure to immunosuppressants at pharmacologically efficacious 
levels. We analyzed each of these parameters in detail.  
 
The infectious potential of the PERV/5_ virus 
stock used for inoculation was analyzed by titration of the virus by end point dilution on human 293 
cells. The infectious titer of PERV/5_ was estimated as 1 · 107 TCID50/ml after 4 weeks of cultivation. 
 
We confirmed our previous data [41] that primary cells of rhesus monkeys and baboons and PBMCs 
of the animals used in this study were susceptible to infection with PERV/5_ (Fig. 2, Table 3). In kinetic 
studies as well as by measuring RT activity in the supernatant of infected PBMCs of rhesus monkeys 
and baboons and viral RNA in pelleted virions as measured by RT-PCR amplification, a productive 
infection in the sense of released virus particles was observed, whereas in the case of pig-tailed 
monkeys only provirus integration but no release of virus particles was observed [42] (Tables 4, 5). 
Similar results were reported by others [43]. It is important to underline that infection was only 
observed with high titer viruses, i.e., PERV/5_ and 293 cell-derived virus, but not with PERV released 
from PK-15 cells (Table 4). Immunological assays such as ELISA or western blot analysis were 
performed as indirect measures to detect a PERV infection assuming that an immunological response 
might be induced even under conditions of immunosuppression at pharmacologically active dose 
levels. The sensitivity of the ELISA was determined by end-point dilution of an anti-p15E serum using 
plates coated with 1 lg/well recombinant p15E of PERV in which it was reached at 1 : 1 000 000. The 
  
sensitivity of the western blot analysis using 10 lg/slot purified PERV proteins was 1 : 1000 using the 
same antip15E serum, the sensitivity of the other western blot analyses were similar.  
 
To analyze integration of proviral DNA into the genome of the animals, DNA from blood cells taken 
every 7 days and DNA isolated from different organs taken after necropsy was analyzed; this was 
carried out simultaneously by conventional PCR at the Robert Koch Institute and by real time PCR at 
Immerge Biotherapeutics. The sensitivity of the PCR method was one PERV/5_-producing 293 cell on 
a background of 1 · 106 uninfected 293 cells, and the sensitivities in the real time PCR for both the 
SLA and PERV pol were quantitative at 10 copies. The exposure to immunosuppressants was 
monitored weekly. In all animals the levels of Cs-A, methylprednisolone, and RAD were in the range of 
generally tolerable but strong immunosuppression (Table 3) [34–36,44–46]. 
 
 
Evaluation during the in vivo study 
 
In order to develop a large animal model system for studies on viral safety that closely resembles the 
clinical situation, three species of non-human primates, namely, baboons, rhesus monkeys, and pig-
tailed monkeys, were inoculated with cell-free PERV/5_, a virus characterized by high titres [32]. 
All animals were inoculated with cell-free PERV/5_ both via the intraperitoneal and intravenous route 
and the follow-up was 260 days. During this follow-up, none of the animals showed antibodies 
to PERV. In addition, plasma was screened for PERV RNA by RT-PCR and for RT activity, also with 
negative results (data not shown). Furthermore, there was no integration of proviral DNA in the cellular 
DNA of blood cells observed in any of the animals using nested PCR with primers specific 
for gag, pol, and env (Fig. 3A). These data indicate that no infection and replication had taken place. 
 
Because none of the animals showed any indication of PERV infection, a second inoculation was 
carried out on day 270. The virus dose was trebled and the virus was inoculated intraperitoneally and 
intravenously, and in addition also subcutaneously and intramuscularly. Furthermore, a C1-esterase 
inhibitor was given to inhibit potential complement activation. To study virus transmission via cell–cell 
contact, rhesus monkey #180 and baboon #7341 received in addition 1 · 109 PERV/5_-producing 293 
cells. To further increase virus exposure, the animals were inoculated again 14 days later on day 284, 
at that time without concomitant C1-esterase treatment.  
 
During follow-up after these inoculations, none of the animals showed either integration of PERV/ 5_ 
proviral DNA in genomic DNA of blood cells (Fig. 3B) or production of antibodies (Fig. 3C). In some 
animals, antibodies to bovine serum albumin, a component of the virus containing supernatant, was 
observed indicating that despite chronic immunosuppression, antibodies against other antigens were 





Rhesus monkey #179 died on day 14 after the first inoculation due to bacterial infection probably 
related to over-immunosuppression. The other animals were euthanized on day 46 (rhesus monkey 
#180), on day 316 (rhesus monkey #178), and on day 336 (baboons #6614 and #7341), respectively. 
Organs were divided and analyzed independently at the Robert Koch Institute and Immerge Bio- 
Therapeutics. DNA was isolated from blood, heart, aorta, lymph nodes, liver, lung, kidneys, and 
spleen, and screened for PERV/5_ proviral DNA using conventional PCR (Robert Koch Institute) and 
real-time PCR (Immerge BioTherapeutics). In none of the samples, amplicons of sequences specific 
for PERV gag, pol, or env could be detected (data not illustrated).  
 
Rhesus monkey #180 developed tumors at several locations including multiple sites in the peritoneum 
as well as in the muscles of chest and legs, in particular at the sites of inoculation of virus-producing 
cells. The presence of tumor cells 
was associated with the presence of the transforming E1 region of Ad 5 in the DNA, indicating that 
the tumor cells originated from the 293 kidney cells inoculated. Using primers specific for the E1 region 
of Ad 5, 293 cells were found in all tumors (Fig. 4). A similar development of tumors has been 
observed after inoculating 293 cells into immunodeprived nude mice [47]. Therefore it is likely that the 
development of the tumors was not due to viral infection with PERV/5_ but due to the tumorigenic 






There is a clear need for a reliable animal model to evaluate the potential risk of PERV transmission 
associated with xenotransplantation. Following the documentation that PERV can be transmitted in 
vitro to primary cells from rhesus monkeys and baboons using high titers of PERV/5_ [42] (Tables 4, 
5), the present study was intended to evaluate the potential risk of PERV transmission to non-human 
primates in vivo. In contrast to in vivo studies using grafts of porcine cells or organs into non-human 
primates [22–30], the present study simulated a ‘‘worst case scenario’’ of virus release. This 
experimental setting was chosen to bypass shortcomings of exploratory clinical trials [13–21]: (i) the 
short survival and function of xenografts; (ii) the small numbers of porcine cells or material other than 
solid organs transplanted [13,16,18–20]; (iii) the encapsulation of cellular xenotransplants in some 
studies [13,19,21]; (iv) the short exposure time and small area of contact in studies using 
extracorporeal perfusion of blood [13–16,20]; and (v) insufficient immunosuppression resulting in short 
survival. We therefore embarked on a protocol in which animals were chronically immunosuppressed 
by Cs-A, methylprednisolone, and RAD at pharmacologically relevant dose levels, and were 
inoculated at two time points at multiple locations with very high titers (1 · 109 to 3 · 109 TCID50) of 
PERV, and subsequently subjected to an 11-month follow-up. The virus used, PERV/5_, infected in 
vitro non-human primate cells more efficiently than others viruses (Table 4). In contrast to pig cell-
derived virus, PERV/5_ produced in human 293 cells does not carry alpha 1,3 Gal epitopes [48] and 
no pig membrane proteins in the viral envelope [49] and is therefore in non-human primates less 
susceptible to the innate and adaptive immune responses. We used the most sensitive assays to 
detect PERV integration in the DNA of PBMCs and various tissues (PCR, nested PCR, and real time 
PCR), and applied indirect immunological testing such as western blot (Fig. 3C), ELISAs, and RT 
assays. To our knowledge, there are no reports in the literature showing provirus integration in cells in 
the absence of an antibody response at later time points after infection with various retroviruses. 
All animals in the present study showed susceptibility to PERV infection in in vitro infection of primary 
cells (Fig. 2, Tables 4, 5). The baboons and rhesus monkeys manifested a productive infection as 
demonstrated by increased RT activity in the supernatant and viral genomic RNA in the pelleted 
viruses but pig-tailed monkeys only demonstrated integrated proviral DNA and no release of virus 
particles [42] (Table 4). It remains to be determined whether the presence of PERV provirus in cells 
from pig-tailed monkeys indicates an infection with provirus integration or an uptake of viral DNA. This 
aside, it remains possible that certain cell types not tested in vitro may be infected in the organism of 
pig-tailed monkeys. Ritzhaupt et al. [43] showed that cell lines from African green monkey, rhesus 
macaque, and baboon were infected with PERV as measured by viral DNA and RNA using PCR and 
RT-PCR assays. Virions released from these infected cells could productively infect naive human cell 
lines confirming our data. We have also shown productive infection of rhesus kidney cells and 
lymphoid cells from chimpanzees (Irgang M, Denner J, unpublished). The fact that PERV does not 
replicate well in primate cells including most human cells suggests that intracellular restriction factor 
such as tripartite motif-a and apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 
(APOBEC) may inhibit virus replication (for review, see [50,51]). These factors may be neutralized 
by higher virus doses, enabling high titer viruses such as PERV/5_ to achieve productive infection. We 
therefore conclude that there is no need to re-evaluate the appropriateness of non-human primates as 
suitable animal models. In contrary, in our experience it is difficult to reach a productive infection in 
most human primary cells and cell lines with exception of 293 kidney cells (which were transformed by 
Ad5 and do not express APOBEC). In contrast to PERVs released by primary pig cells and by pig cell 
lines, the PERV/5_ used in this study is characterized by very high infectious titers (1 · 107 TCID50/ml) 
[32,52]. This enhanced replication potential is due to multiple transcription factor (TF) binding sites for 
the nuclear TF nuclear factor-Y (NF-Y). We used high doses of this virus to inoculate the animals and 
to simulate a situation of a massive release of PERV from an implanted porcine xenotransplant. Even 
mimicking this ‘‘worst-case’’ scenario, none of the animals showed any evidence of infection during a 
follow up to 11 months (Fig. 3). This result is remarkable in view of (i) transmission of PERV in vitro to 
cells of the same animals; (ii) the profound chronic immunosuppression at pharmacologically 
efficacious dose levels; (iii) multiple application of cell-free high-titer PERV; (iv) the use of cell-
associated virus in addition to cell-free virus in some animals; (v) various sites and administration 
routes of virus, and (vi) the long-term follow-up period. One explanation of the difference between the 
in vitro and in vivo data might be the efficient elimination of PERVs by the naturally existing immunity 
which is not affected by conventional immunosuppression. The complement system and pre-formed 
natural antibodies may be involved in this process [53–56]. Innate host defense mechanisms might 
explain the fact that the initial virus load in infectivity studies has to be much higher than that used in 
vitro infection [56]. In studies using guinea pigs and lambs a transient PERV transmission was 
observed after inoculation of virus or applying pig tissue [57,58]. This transient infection was observed 
in the first days after infection and declined later. Although in this study cells could not be collected in 
  
the first week after PERV inoculation, long-term infection (up to 1 yr) in the presence of 
immunosuppressant was found negative (Fig. 1–3). In order to avoid microchimerism, we applied cell-
free virus and in order to allow cell–cell contact as part of the worst case scenario, we applied cells 
producing large quantities of human cell adapted virus. In contrast to virus released from implanted 
cell aggregates [59] this virus is characterized by a virus titer, absence of alpha 1,3 Gal epitopes and 
absence of pig antigens. Data on productive PERV transmission in vivo do not exist, and hence the 
situation in human xenotransplant recipients remains open for speculation. Literature documents 
indicate that PERV may not easily infect target individuals in vivo, i.e., first xenotransplantation 
patients [13–21] including liver failure patients receiving ex vivo perfusions using porcine hepatocytes 
[13–15,20] and butchers having often blood–blood contact with pigs [17]. This is underscored by pig to 
monkey transplantations [22–30], in vivo infection experiments with small animals (for review see [60]), 
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Fig. 1. Time schedule of the in vivo porcine endogenous retroviruses (PERV) inoculations: 1, daily 
application of cyclosporine A started 5 days before first PERV inoculation; 2, stop of 
immunosuppression for rhesus monkey #178; 3, stop of immunosuppressionfor baboon #7341; 4, stop 
of immunosuppression for baboon #6614; 5, start of immunosuppression 10 days before second 






Fig. 2. In vitro infection of primary peripheral blood mononuclear cells (PBMCs) from rhesus monkeys 
and baboons used in the in vivo experiment. 5 · 106 PBMCs from rhesus monkeys and baboons were 
incubated for 24 h with 10 ml of virus-containing supernatant of 1 · 107 porcine endogenous 
retroviruses (PERV)/5_-producing 293 cells (Titer 1 · 107 TCID50/ml; tissue culture infectious doses). 
DNA was isolated 10 days after inoculation and integration of proviral DNA was demonstrated by 
using PCR and primers specific for PERV-env A, uninfected ()), and infected (+) PBMCs. DNA from 
uninfected ()) and PERV/5_-infected (+) 293 cells was used as negative and positive controls. Primers 














Fig. 3. PCR analysis and western blot 
analysis. (A) PCR analysis of peripheral blood 
mononuclear cells (PBMCs) taken 
from rhesus monkeys and baboons 260 days 
after inoculation with porcine endogenous 
retroviruses (PERV)/5_ in vivo and using 
primers specific for b-actin (1), for PERV envA 
(2), gag (3), and pol (4). DNA from PERV/5_-
infected 293 cells was 
used as positive control. (B) Nested PCR with 
DNA from PBMCs taken at day 336 from 
rhesus monkey #178 (1), rhesus monkey #180 
(2), baboon #6614 (3), and baboon #7341 (4) 
was performed using primers specific for the 
pol gene of PERV. 
DNA from uninfected PBMCs of rhesus 
monkey #180 (5), baboon #6614 (6), and 
uninfected 293 cells (7) were used as 
negative control, DNA from PERV/5_-infected 
293 cells was used as positive control (8). 
Primers for b-actin were used to 
control loading of DNA. (C) Western blot 
analysis of sera from inoculated non-human 
primates obtained 12 weeks postinoculation 
with PERV/5_ (Nem—pig tailed monkey, 
Rh—rhesus monkey, Ba—baboon). To control 
the quality of the blot and the blotting 
procedure, animal sera against several 




Fig. 4. PCR analysis of different tumors from 
rhesus monkey #180. PCR was performed using 
primers specific for porcine endogenous 
retroviruses (PERV) pol. Presence of 293 cells in 
these tumors was shown by PCR using primers 
specific for E1 region of adenovirus 5 (Ad 5). 1–3: 
Tumors of the peritoneum; 4, 5: tumors of the 
pectoral muscles; 6: tumor of the leg. DNA from 
PERV/5_-infected 293 cells (7) and uninfected        
rhesus monkey peripheral blood mononuclear cells (8)   
were used as positive and negative control,   primers 
for b-actin were used to control the loading of DNA, 9: 
100 bp ladder. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
  
